Patents Assigned to Viron Therapeutics
-
Publication number: 20230414650Abstract: The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc at appropriate concentrations to mitigate infections by enveloped viruses, such as COVID-19 virus (SARS-CoV-2), influenza and HIV. While the different forms of cyclodextrin prevent the entry of coated viruses into host cells by extracting and sequestering cholesterol molecules at the virus envelope and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. SUBSTANCE: This formulation is adapted for both surface use and introduction to a subject by dispersal, utilizing the known methods of measured nasal sprays or inhalers, wet wipes and medicated masks. The formulation is introduced in the form of an aqueous phosphate buffered saline pH 7.5 solution, containing 0.Type: ApplicationFiled: March 19, 2021Publication date: December 28, 2023Applicant: Viron Therapeutics LLCInventors: Bhanu Pratap Jena, Octavian Bucur
-
Publication number: 20230082992Abstract: The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-CoV-2, influenza and HIV/AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.Type: ApplicationFiled: September 11, 2021Publication date: March 16, 2023Applicant: Viron Therapeutics LLCInventor: Bhanu Pratap Jena
-
Publication number: 20120270793Abstract: Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.Type: ApplicationFiled: October 21, 2010Publication date: October 25, 2012Applicant: Viron Therapeutics Inc.Inventor: Alexandra R. Lucas
-
Patent number: 8268331Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: GrantFiled: May 7, 2009Date of Patent: September 18, 2012Assignee: Viron Therapeutics, Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 8227569Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: GrantFiled: March 2, 2010Date of Patent: July 24, 2012Assignee: Viron Therapeutics Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Publication number: 20110064757Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: ApplicationFiled: May 7, 2009Publication date: March 17, 2011Applicant: Viron Therapeutics, Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 7906483Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.Type: GrantFiled: February 23, 2009Date of Patent: March 15, 2011Assignee: Viron Therapeutics Inc.Inventors: Alexandra Lucas, Z. Robert Zhong, D. Grant McFadden
-
Publication number: 20100331524Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: ApplicationFiled: March 2, 2010Publication date: December 30, 2010Applicant: Viron Therapeutics Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 7745396Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.Type: GrantFiled: September 7, 2007Date of Patent: June 29, 2010Assignee: Viron Therapeutics Inc.Inventor: Alexandra Lucas
-
Patent number: 7718368Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: GrantFiled: August 17, 2006Date of Patent: May 18, 2010Assignee: Viron Therapeutics Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 7585507Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: GrantFiled: May 9, 2005Date of Patent: September 8, 2009Assignee: Viron Therapeutics Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 7514405Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.Type: GrantFiled: March 13, 2003Date of Patent: April 7, 2009Assignee: Viron Therapeutics Inc.Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden
-
Publication number: 20090011979Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immunoinflammatory disorders.Type: ApplicationFiled: August 17, 2006Publication date: January 8, 2009Applicant: Viron Therapeutics, Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 7419670Abstract: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1/immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.Type: GrantFiled: September 28, 2001Date of Patent: September 2, 2008Assignee: Viron Therapeutics, Inc.Inventors: Robert Z. Zhong, Alexandra Lucas, Grant D. McFadden
-
Publication number: 20080070841Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.Type: ApplicationFiled: September 7, 2007Publication date: March 20, 2008Applicant: Viron Therapeutics, Inc.Inventor: Alxandria Lucas
-
Patent number: 7285530Abstract: Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.Type: GrantFiled: October 21, 2005Date of Patent: October 23, 2007Assignee: Viron Therapeutics, Inc.Inventor: Alexandra Lucas
-
Publication number: 20060286125Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: ApplicationFiled: May 9, 2005Publication date: December 21, 2006Applicant: Viron Therapeutics, Inc.Inventors: Grant McFadden, Karim Essani
-
Patent number: 7101559Abstract: The invention generally features the use of Yaba monkey tumor virus nucleic acid molecules and polypeptides for the treatment or prevention of immune-related diseases.Type: GrantFiled: June 4, 2003Date of Patent: September 5, 2006Assignee: Viron Therapeutics, Inc.Inventors: Grant McFadden, Alexandra Lucas, Xing Li
-
Patent number: 6894155Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: GrantFiled: October 11, 2001Date of Patent: May 17, 2005Assignee: Viron TherapeuticsInventors: Grant McFadden, Karim Essani
-
Publication number: 20030171263Abstract: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.Type: ApplicationFiled: March 13, 2003Publication date: September 11, 2003Applicant: Viron Therapeutics, Inc.Inventors: Alexandra Lucas, Robert Zhong, D. Grant McFadden